Tonix Pharmaceuticals Holding Corp
Company Profile
Business description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Contact
200 Connell Drive
Suite 3100
Berkeley HeightsNJ07928
USAT: +1 862 799-8599
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
142
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
stocks
Vegemite owner’s shares remain expensive on normalising profits.
stocks
Ask the analyst: Where does GYG stand following its US exit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,051.10 | 25.30 | 0.28% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,638.24 | 288.21 | 1.23% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,081.46 | 662.61 | -0.95% |
| NZX 50 Index | 13,697.07 | 78.65 | 0.58% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,846.20 | 27.90 | 0.32% |
| SSE Composite Index | 4,032.17 | 11.47 | -0.28% |